Slow progress on Pfizer's plan to sell drugs to low-income nations at not-for-profit price, says CEO
Pfizer has so far signed up less than a quarter of the countries targeted under a plan to make its medicines available to the ...
Pfizer Sickle Cell Drug Suspended by Europe in New Setback
All data considered, the benefit of the therapy, Oxbryta, “no longer outweighs the risk,” Pfizer said in a statement ...
STAT3d
Pharmalittle: We’re reading about Pfizer pulling a sickle cell pill, Moderna getting scolded, and more
Pfizer is removing its Oxbryta pill for sickle cell disease from all markets globally due to safety risks, including deaths.
Can Pfizer Stock Rise 2x To $60?
Although it has been plagued by multiple issues, including falling sales with lower demand for its Covid-19 products, and an ...
Deaths lead Pfizer to pull sickle cell drug at center of $5 billion Bay Area buyout
Pfizer had big hopes for a sickle-cell disease drug, as did those suffering from the disease. Things didn't turn out as ...
BioSpace2d
Pfizer’s Oxbryta Withdrawal Leaves Sickle Cell Community Scrambling, Investors Reeling
Pfizer’s sudden market withdrawal of sickle cell therapy Oxbryta, which some analysts predicted would reach $750 million in ...
Pfizer: A 6% Yielding Value Deal
Pfizer remains an attractive capital return play with a 10X P/E ratio, despite concerns about post-COVID revenue declines.
FiercePharma3d
Pfizer issues global market withdrawal of sickle cell disease therapy Oxbryta
Pfizer will voluntarily pull its sickle cell disease (SCD) drug Oxbryta from all markets worldwide, a major blow to a $5.4 ...
Pfizer yanks sickle-cell treatment worldwide after possible link to deaths
Pfizer Inc. said late Wednesday it was withdrawing a sickle-cell drug from markets worldwide and discontinuing clinical ...
Here is What Jim Cramer Likes Pfizer Inc. (NYSE:PFE)
We recently published a list of Jim Cramer’s Latest Portfolio: Top 9 Stocks to Buy and Sell. Since Pfizer Inc. (NYSE:PFE) ...